Insider · CIK 0001814876

Coyne Terrance P.

Reports to the SEC for 1 company · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001814876

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-13	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−1,772 sh	$59.14	−$105K	0
2026-08-13	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−9,230 sh	$58.59	−$541K	1,772
2026-08-07	RPRXRoyalty Pharma plc · Class E Ordinary SharesG Gift	EVP & CFO	GGift	−18.5K sh	—	—	1,788,777
2026-08-05	RPRXRoyalty Pharma plcA Award	EVP & CFO	AAward	+11K sh	—	—	11,002
2026-05-26	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−64.4K sh	$53.98	−$3.48M	0
2026-05-06	RPRXRoyalty Pharma plcA Award	EVP & CFO	AAward	+24.3K sh	—	—	64,399
2026-04-28	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−32.9K sh	$49.78	−$1.64M	0
2026-04-28	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−1,875 sh	$49.78	−$93.3K	40,136
2026-04-01	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−1,875 sh	$48.33	−$90.6K	42,011
2026-04-01	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−32.9K sh	$48.33	−$1.59M	32,916
2026-03-23	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−32.9K sh	$45.53	−$1.5M	65,832
2026-03-23	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−1,875 sh	$45.53	−$85.4K	43,886
2026-03-02	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−10.4K sh	$47.01	−$490K	98,748
2026-03-02	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−1,292 sh	$46.67	−$60.3K	46,344
2026-03-02	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−22.5K sh	$46.67	−$1.05M	109,177
2026-03-02	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−583 sh	$47.01	−$27.4K	45,761
2026-02-23	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−32.9K sh	$45.32	−$1.49M	131,664
2026-02-23	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−1,875 sh	$45.32	−$85K	47,636
2026-02-11	RPRXRoyalty Pharma plcA Award	EVP & CFO	AAward	+26.6K sh	—	—	49,511
2026-02-04	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−19.1K sh	$43.29	−$826K	164,580
2026-02-04	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−1,087 sh	$43.29	−$47.1K	22,885
2026-02-03	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−6,195 sh	$42.84	−$265K	23,972
2026-02-03	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−109K sh	$42.84	−$4.66M	183,656
2026-02-02	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−5,843 sh	$42.08	−$246K	30,167
2026-02-02	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−103K sh	$42.08	−$4.32M	292,415
2026-01-20	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−65.8K sh	$39.35	−$2.59M	394,996
2026-01-20	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−3,750 sh	$39.35	−$148K	36,010
2026-01-02	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−65.8K sh	$38.42	−$2.53M	460,828
2026-01-02	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−3,750 sh	$38.42	−$144K	39,760
2025-12-15	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−3,750 sh	$38.36	−$144K	43,510
2025-12-15	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−65.8K sh	$38.36	−$2.53M	526,660
2025-12-01	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−65.8K sh	$39.87	−$2.62M	592,492
2025-12-01	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−3,750 sh	$39.87	−$149K	47,260
2025-11-24	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−10.7K sh	$37.96	−$406K	658,324
2025-11-24	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−624 sh	$37.96	−$23.7K	51,010
2025-11-24	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−55.1K sh	$38.67	−$2.13M	669,010
2025-11-24	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−3,126 sh	$38.67	−$121K	51,634
2025-11-17	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−3,750 sh	$39.30	−$147K	54,760
2025-11-17	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−65.8K sh	$39.30	−$2.59M	724,156
2025-11-05	RPRXRoyalty Pharma plcA Award	EVP & CFO	AAward	+6,168 sh	—	—	58,510
2025-08-08	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	EVP & CFO	GGift	−1,000 sh	—	—	43,350
2025-08-06	RPRXRoyalty Pharma plcA Award	EVP & CFO	AAward	+3,696 sh	—	—	52,342
2025-05-16	RPRXRoyalty Pharma plc · Class E Ordinary SharesA Award	EVP & CFO	AAward	+1.81M sh	—	—	1,807,277
2025-05-08	RPRXRoyalty Pharma plcA Award	EVP & CFO	AAward	+48.6K sh	—	—	48,646
2024-08-12	RPRXRoyalty Pharma plc · ICAI InterestsG Gift	EVP & CFO	GGift	−2,000 sh	—	—	44,350
2023-08-10	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−37.5K sh	$30.75	−$1.15M	790,000
2023-08-09	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−37.5K sh	$30.72	−$1.15M	827,500
2023-08-08	RPRXRoyalty Pharma plc · ICAI InterestsG Gift	EVP & CFO	GGift	−1,650 sh	—	—	46,350
2023-07-13	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−37.5K sh	$30.93	−$1.16M	865,000
2023-07-12	RPRXRoyalty Pharma plcS Sale	EVP & CFO	SSale	−37.5K sh	$31.07	−$1.17M	902,500

Recent filings

Accepted (ET)
Aug 174
Coyne Terrance P.0001814876-26-000027
SEC(opens sec.gov)
Aug 74
Coyne Terrance P.0001814876-26-000025
SEC(opens sec.gov)
May 284
Coyne Terrance P.0001814876-26-000022
SEC(opens sec.gov)
May 84
Coyne Terrance P.0001814876-26-000020
SEC(opens sec.gov)
Apr 304
Coyne Terrance P.0001814876-26-000018
SEC(opens sec.gov)
Apr 24
Coyne Terrance P.0001814876-26-000016
SEC(opens sec.gov)
Mar 254
Coyne Terrance P.0001814876-26-000014
SEC(opens sec.gov)
Mar 44
Coyne Terrance P.0001814876-26-000012
SEC(opens sec.gov)
Feb 254
Coyne Terrance P.0001814876-26-000010
SEC(opens sec.gov)
Feb 134
Coyne Terrance P.0001814876-26-000008
SEC(opens sec.gov)
Feb 44
Coyne Terrance P.0001814876-26-000006
SEC(opens sec.gov)

Companies

Royalty Pharma plcEVP & CFORPRX

Address

C/O ROYALTY PHARMA PLC 110 EAST 59TH STREET

NEW YORK, NY, 10022